You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,859,572


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,859,572
Title:Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
Abstract: This invention relates to novel sulfone 2I3-dihydroimidazo[1 l2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other active ingredients.
Inventor(s): Hentemann; Martin F. (Carlisle, MA), Scott; William (Guilford, CT), Wood; Jill (Ft. Collins, CO), Johnson; Jeffrey (North Branford, CT), Redman; Aniko (Durham, NC), Bullion; Ann-Marie (King of Prussia, PA), Guernon; Leatte (Moodus, CT)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:12/812,911
Patent Claims:1. A compound having the formula: ##STR00106## or a physiologically acceptable salt thereof, wherein: R.sup.1 is a heteroaryl optionally substituted with 1, 2 or 3 R.sup.4 groups; R.sup.2 is hydrogen, alkoxy, heterocyclylalkyl, heterocyclylalkoxy or R.sup.3; each occurrence of R.sup.3 is independently ##STR00107## --Y--SO.sub.q--Z or --Y--N(R.sup.5)--SO.sub.q--Z; each occurrence of X is independently --C(R.sup.5)-- or --N--; each occurrence of Y is independently a bond, alkoxy, alkoxyalkoxy or arylalkoxy; each occurrence of Z is independently alkyl, --N(R.sup.6)(R.sup.6'), or -heterocyclylalkyl optionally substituted with 1, 2 or 3 R.sup.4 groups; each occurrence of R.sup.4 may be the same or different and is independently amino, halogen, amino, alkylamino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl; each occurrence of R.sup.5 is independently hydrogen or alkyl; each occurrence of R.sup.6 and R.sup.6' may be the same or different and is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclyl, or heterocyclylalkyl, wherein R.sup.6 and R.sup.6' may be attached to each other to form a heterocyclic ring through a bond or through one or more O, C, N, S, SO.sub.q or carbonyl, and wherein at least one N is part of the heterocyclic ring; and each occurrence of n is independently an integer from 1-4; and each occurrence of p is independently an integer from 0-2.

2. The compound of claim 1, wherein R.sup.2 is alkoxy.

3. The compound of claim 2, wherein R.sup.2 is methoxy.

4. The compound of claim 1, wherein R.sup.1 is pyridine, pyrimidine or thiazole, optionally substituted with 1, 2 or 3 R.sup.4 groups.

5. The compound of claim 4, wherein R.sup.1 is pyridine, pyrimidine or thiazole, optionally substituted with 1 or 2 amino or methyl groups.

6. The compound of claim 5, wherein R.sup.1 is pyridin-3-yl.

7. The compound of claim 1, wherein R.sup.2 is N-morpholino-alkoxy.

8. The compound of claim 1, wherein R.sup.3--Y--SO.sub.2--Z or --Y--NH--SO.sub.2--Z.

9. The compound of claim 8, wherein Z is N-morpholino, methyl, or alkylamino.

10. The compound of claim 1, wherein: R.sup.1 is a heteroaryl optionally substituted with 1 R.sup.4 group; R.sup.2 is alkoxy or heterocyclylalkoxy; R.sup.3 is independently ##STR00108## --Y--SO.sub.2--Z or --Y--NH--SO.sub.2--Z; each occurrence of Y is independently alkoxy, alkoxyalkoxy, or arylalkoxy; each occurrence of Z is independently alkyl, --N(R.sup.6)(R.sup.6'), or -heterocyclylalkyl; each occurrence of R.sup.4 may be the same or different and is independently amino, halogen, amino, alkylamino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalklyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; each occurence of R.sup.6 and R.sup.6' may be the same or different and is independently hydrogen or alkyl; and each occurrence of n is independently an integer from 1-4.

11. The compound of claim 10, wherein: R.sup.1 is pyridine, pyrimidine, or thiazole optionally substituted with one amino or methyl group; R.sup.2 is methoxy or 3-morpholin-4-ylpropoxy; R.sup.3 is independently ##STR00109## --Y--SO.sub.2--Z or --Y--NH--SO.sub.2--Z; each occurrence of Y is independently alkoxy, alkoxyalkoxy, or arylalkoxy; and each occurrence of Z is independently methyl, morpholin-4-yl, or dimethylamino.

12. A compound having the formula: N-(8-{3-[(ethylsulfonyl)amino]propoxy}-7-methoxy-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl)nicotinamide; N-[7-methoxy-8-(2-{2-[(propylsulfonyl)amino]ethoxy}ethoxy)-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(2-{2-[(phenylsulfonyl)amino]ethoxy}ethoxy)-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-methoxy-8-(2-{2-[(methylsulfonyl)amino]ethoxy}ethoxy)-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl]nicotinamide; N-{7-methoxy-8-[2-(2-{[(4-methylphenyl)sulfonyl]amino}ethoxy)ethoxy]-2,3-- dihydroimidazo[1,2-c]quinazolin-5-yl}nicotinamide; N-{8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}nicotinamide; N-(8-{3-[(4-methylpiperazin-1-yl)sulfonyl]propoxy}-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl)nicotinamide; N-(8-{[4-(methylsulfonyl)benzyl]oxy}-2,3-dihydroimidazo[1,2-c]quinazolin-- 5-yl)nicotinamide; 2,4-dimethyl-N-(8-{[4-(methylsulfonyl)benzyl]oxy}-2,3-dihydroimidazo[1,2-- c]quinazolin-5-yl)-1,3-thiazole-5-carboxamide; N-{8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}pyrimidine-5-carboxamide; 2-amino-N-{8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl}pyrimidine-5-carboxamide; 6-amino-N-{8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2-c- ]quinazolin-5-yl}nicotinamide; N-(7-methoxy-8-{3-[(4-methylpiperazin-1-yl)sulfonyl]propoxy}-2,3-dihydroi- midazo[1,2-c]quinazolin-5-yl)nicotinamide; N-(7-methoxy-8-{[4-(methylsulfonyl)benzyl]oxy}-2,3-dihydroimidazo[1,2-c]q- uinazolin-5-yl)nicotinamide; N-{7-methoxy-8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl}nicotinamide; N-{8-[3-(1,1-dioxidothiomorpholin-4-yl)propoxy]-7-methoxy-2,3-dihydroimid- azo[1,2-c]quinazolin-5-yl}nicotinamide; N-(8-{3-[(diethylamino)sulfonyl]propoxy}-7-methoxy-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl)nicotinamide; N-(8-{3-[(dimethylamino)sulfonyl]propoxy}-7-methoxy-2,3-dihydroimidazo[1,- 2-c]quinazolin-5-yl)nicotinamide; N-{7-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazo- lin-5-yl}nicotinamide; N-(7-{3-[(4-methylpiperazin-1-yl)sulfonyl]propoxy}-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl)nicotinamide; N-{7-[3-(1,1-dioxidothiomorpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]- quinazolin-5-yl}nicotinamide; N-(7-{[4-(methylsulfonyl)benzyl]oxy}-2,3-dihydroimidazo[1,2-c]quinazolin-- 5-yl)nicotinamide; N-(7-{3-[(dimethylamino)sulfonyl]propoxy}-2,3-dihydroimidazo[1,2-c]quinaz- olin-5-yl)nicotinamide; N-{8-(3-morpholin-4-ylpropoxy)-7-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-- dihydroimidazo[1,2-c]quinazolin-5-yl}nicotinamide; N-[7-{3-[(4-methylpiperazin-1-yl)sulfonyl]propoxy}-8-(3-morpholin-4-ylpro- poxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-{3-[(diethylamino)sulfonyl]propoxy}-8-(3-morpholin-4-ylpropoxy)-2,3-- dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-{3-[(dimethylamino)sulfonyl]propoxy}-8-(3-morpholin-4-ylpropoxy)-2,3- -dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 2-amino-N-(7-methoxy-8-{[4-(methylsulfonyl)benzyl]oxy}-2,3-dihydroimidazo- [1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 2-amino-N-(8-{3-[(dimethylamino)sulfonyl]propoxy}-7-methoxy-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 6-amino-N-(8-{3-[(dimethylamino)sulfonyl]propoxy}-7-methoxy-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)nicotinamide; 6-amino-N-{8-[3-(1,1-dioxidothiomorpholin-4-yl)propoxy]-7-methoxy-2,3-dih- ydroimidazo[1,2-c]quinazolin-5-yl}nicotinamide; 6-amino-N-(7-methoxy-8-{[4-(methylsulfonyl)benzyl]oxy}-2,3-dihydroimidazo- [1,2-c]quinazolin-5-yl)nicotinamide; 2-amino-N-{8-[3-(1,1-dioxidothiomorpholin-4-yl)propoxy]-7-methoxy-2,3-dih- ydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; 6-amino-N-{7-methoxy-8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl}nicotinamide; 2-amino-N-{7-methoxy-8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; N-[7-{[4-(methylsulfonyl)benzyl]oxy}-8-(3-morpholin-4-ylpropoxy)-2,3-dihy- droimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 8-(3-morpholin-4-ylpropoxy)-5-[(pyridin-3-ylcarbonyl)amino]-2,3-dihydroim- idazo[1,2-c]quinazolin-7-yl methanesulfonate; or a physiologically acceptable salt thereof.

13. The compound of claim 10 having the formula: N-{7-methoxy-8-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-dihydroimidazo[1,2- -c]quinazolin-5-yl}nicotinamide; N-{8-[3-(1,1-dioxidothiomorpholin-4-yl)propoxy]-7-methoxy-2,3-dihydroimid- azo[1,2-c]quinazolin-5-yl}nicotinamide; N-(8-{3-[(dimethylamino)sulfonyl]propoxy}-7-methoxy-2,3-dihydroimidazo[1,- 2-c]quinazolin-5-yl)nicotinamide; N-{8-(3-morpholin-4-ylpropoxy)-7-[3-(morpholin-4-ylsulfonyl)propoxy]-2,3-- dihydroimidazo[1,2-c]quinazolin-5-yl}nicotinamide; N-[7-{3-[(dimethylamino)sulfonyl]propoxy}-8-(3-morpholin-4-ylpropoxy)-2,3- -dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide; 2-amino-N-(8-{3-[(dimethylamino)sulfonyl]propoxy}-7-methoxy-2,3-dihydroim- idazo[1,2-c]quinazolin-5-yl)pyrimidine-5-carboxamide; 2-amino-N-{8-[3-(1,1-dioxidothiomorpholin-4-yl)propoxy]-7-methoxy-2,3-dih- ydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide; N-[7-methoxy-8-(2-{2-[(methylsulfonyl)amino]ethoxy}ethoxy)-2,3-dihydroimi- dazo[1,2-c]quinazolin-5-yl]nicotinamide; N-[7-{[4-(methylsulfonyl)benzyl]oxy}-8-(3-morpholin-4-ylpropoxy)-2,3-dihy- droimidazo[1,2-c]quinazolin-5-yl]nicotinamide or a physiologically acceptable salt thereof.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable diluent or carrier.

15. The pharmaceutical composition of claim 14, further comprising an anti-hyper-proliferative, anti-inflammatory, analgesic, immunoregulatory, diuretic, anti-arrhythmic, anti-hypercholesterolemic, anti-diabetic, anti-dyslipidemia, anti-diabetic or antiviral agent.

16. The pharmaceutical composition of claim 15, wherein the further active compound is gemcitabine, paclitaxel, cisplatin, carboplatin, sodium butyrate, 5-FU, doxirubicin, tamoxifen, etoposide, trastumazab, gefitinib, intron A, rapamycin, 17-AAG, U0126, insulin, an insulin derivative, a PPAR ligand, a sulfonylurea drug, an .alpha.-glucosidase inhibitor, a biguanide, a PTP-1B inhibitor, a DPP-IV inhibitor, a 11-beta-HSD inhibitor, GLP-1, a GLP-1 derivative, GIP, a GIP derivative, PACAP, a PACAP derivative, secretin, secretin derivative, aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, aminoglutethimide, amifostine, amrubicin, amsacrine, anastrozole, anzmet, aranesp, arglabin, arsenic trioxide, aromasin, 5-azacytidine, azathioprine, BCG or tice BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, broxuridine, bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, cefesone, celmoleukin, cerubidine, chlorambucil, cisplatin, cladribine, cladribine, clodronic acid, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, DaunoXome, decadron, decadron phosphate, delestrogen, denileukin diftitox, depo-medrol, deslorelin, dexrazoxane, diethylstilbestrol, diflucan, docetaxel, doxifluridine, doxorubicin, dronabinol, DW-166HC, eligard, elitek, ellence, emend, epirubicin, epoetin alfa, epogen, eptaplatin, ergamisol, estrace, estradiol, estramustine phosphate sodium, ethinyl estradiol, ethyol, etidronic acid, etopophos, etoposide, fadrozole, farston, filgrastim, finasteride, fligrastim, floxuridine, fluconazole, fludarabine, 5-fluorodeoxyuridine monophosphate, 5-fluorouracil (5-FU), fluoxymesterone, flutamide, formestane, fosteabine, fotemustine, fulvestrant, gammagard, gemcitabine, gemtuzumab, gleevec, gliadel, goserelin, granisetron HCl, histrelin, hycamtin, hydrocortone, eyrthro-hydroxynonyladenine, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, interferon alpha, interferon-alpha 2, interferon alfa-2A, interferon alfa-2B, interferon alfa-n1, interferon alfa-n3, interferon beta, interferon gamma-1a, interleukin-2, intron A, iressa, irinotecan, kytril, lentinan sulphate, letrozole, leucovorin, leuprolide, leuprolide acetate, levamisole, levofolinic acid calcium salt, levothroid, levoxyl, lomustine, lonidamine, marinol, mechlorethamine, mecobalamin, medroxyprogesterone acetate, megestrol acetate, melphalan, menest, 6-mercaptopurine, Mesna, methotrexate, metvix, miltefosine, minocycline, mitomycin C, mitotane, mitoxantrone, Modrenal, Myocet, nedaplatin, neulasta, neumega, neupogen, nilutamide, nolvadex, NSC-631570, OCT-43, octreotide, ondansetron HCl, orapred, oxaliplatin, paclitaxel, pediapred, pegaspargase, Pegasys, pentostatin, picibanil, pilocarpine HCl, pirarubicin, plicamycin, porfimer sodium, prednimustine, prednisolone, prednisone, premarin, procarbazine, procrit, raltitrexed, rebif, rhenium-186 etidronate, rituximab, roferon-A, romurtide, salagen, sandostatin, sargramostim, semustine, sizofiran, sobuzoxane, solu-medrol, sparfosic acid, stem-cell therapy, streptozocin, strontium-89 chloride, synthroid, tamoxifen, tamsulosin, tasonermin, tastolactone, taxotere, teceleukin, temozolomide, teniposide, testosterone propionate, testred, thioguanine, thiotepa, thyrotropin, tiludronic acid, topotecan, toremifene, tositumomab, trastuzumab, treosulfan, tretinoin, trexall, trimethylmelamine, trimetrexate, triptorelin acetate, triptorelin pamoate, UFT, uridine, valrubicin, vesnarinone, vinblastine, vincristine, vindesine, vinorelbine, virulizin, zinecard, zinostatin stimalamer, zofran, ABI-007, acolbifene, actimmune, affinitak, aminopterin, arzoxifene, asoprisnil, atamestane, atrasentan, sorafenib, avastin, CCI-779, CDC-501, celebrex, cetuximab, crisnatol, cyproterone acetate, decitabine, DN-101, doxorubicin-MTC, dSLIM, dutasteride, edotecarin, eflornithine, exatecan, fenretinide, histamine dihydrochloride, histrelin hydrogel implant, holmium-166 DOTMP, ibandronic acid, interferon gamma, intron-PEG, ixabepilone, keyhole limpet hemocyanin, L-651582, lanreotide, lasofoxifene, libra, lonafarnib, miproxifene, minodronate, MS-209, liposomal MTP-PE, MX-6, nafarelin, nemorubicin, neovastat, nolatrexed, oblimersen, onco-TCS, osidem, paclitaxel polyglutamate, pamidronate disodium, PN-401, QS-21, quazepam, R-1549, raloxifene, ranpirnase, 13-cis-retinoic acid, satraplatin, seocalcitol, T-138067, tarceva, taxoprexin, thymosin alpha 1, tiazofurine, tipifarnib, tirapazamine, TLK-286, toremifene, TransMID-107R, valspodar, vapreotide, vatalanib, verteporfin, vinflunine, Z-100, zoledronic acid or combinations thereof.

Details for Patent 8,859,572

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Teknika Llc TICE BCG bcg live For Injection 102821 06/21/1989 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
Baxalta Us Inc. GAMMAGARD, GAMMAGARD S/D, IVEEGAM immune globulin intravenous (human) For Injection 103133 02/18/1986 ⤷  Try a Trial 2039-02-26
Baxalta Us Inc. GAMMAGARD, GAMMAGARD S/D, IVEEGAM immune globulin intravenous (human) For Injection 103133 07/27/2000 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.